Patent ID: 8357399

Claim:
An oral dosage form comprising: (i) an opioid agonist selected from the group consisting of oxycodone, hydromorphone, hydrocodone, morphine, oxymorphone, pharmaceutically acceptable salts thereof and mixtures thereof, and (ii) a sequestered opioid antagonist composition comprising an opioid antagonist selected from the group consisting of naltrexone and pharmaceutically acceptable salts thereof, and a hydrophobic material in an amount which substantially prevents release of the opioid antagonist from the intact dosage form such that the dosage form which is intact releases at least 0.025 mg, but less than 0.25 mg, of the naltrexone at 1 hour, and the dosage form which is tampered with releases 0.25 mg or more of naltrexone at 1 hour, based on an in-vitro dissolution in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37° C., wherein the opioid agonist is separated from the opioid antagonist by the hydrophobic material.